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Protein misfoldingPrimary Hyperoxaluria Type I (PH1) is a severe rare disorder of metabolism due to inherited mutations on liver
peroxisomal alanine:glyoxylate aminotransferase (AGT), a pyridoxal 5′-phosphate (PLP)-dependent enzyme
whose deﬁciency causes the deposition of calcium oxalate crystals in the kidneys and urinary tract. PH1 is an ex-
tremely heterogeneous disease and there aremore than 150 disease-causingmutations currently known,most of
which are missense mutations. Moreover, the molecular mechanisms by which missense mutations lead to AGT
deﬁciency span from structural, functional to subcellular localization defects. Gly161 is a highly conserved resi-
due whose mutation to Arg, Cys or Ser is associated with PH1. Here we investigated the molecular bases of the
AGT deﬁcit caused by Gly161 mutations with expression studies in a mammalian cellular system paired with
biochemical analyses on the puriﬁed recombinant proteins. Our results show that the mutations of Gly161
(i) strongly reduce the expression levels and the intracellular half-life of AGT, and (ii) make the protein in the
apo-form prone to an electrostatically-driven aggregation in the cell cytosol. The coenzyme PLP, by shifting the
equilibrium from the apo- to the holo-form, is able to reduce the aggregation propensity of the variants, thus
partly decreasing the effect of the mutations. Altogether, these results shed light on the mechanistic details
underlying the pathogenicity of Gly161 variants, thus expanding our knowledge of the enzymatic phenotypes
leading to AGT deﬁciency.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Primary Hyperoxaluria Type I (PH1, MIM 259900) is an autosomal
recessive metabolic disorder caused by inherited mutations in the
AGXT gene encoding liver peroxisomal alanine:glyoxylate aminotrans-
ferase (AGT) [1]. AGT is a pyridoxal 5′-phosphate (PLP)-dependent en-
zyme that catalyzes the transamination of L-alanine and glyoxylate to
pyruvate and glycine, respectively. The protein is dimeric and has an
overall structure similar to that of other human Fold Type I aminotrans-
ferases [2,3]. Each subunit is made up of a large domain, comprising
most of the active site and the dimerization interface, an N-terminal ex-
tension that wraps over the surface of the neighboring subunit, and a
small domain, comprising regions involved in the interaction with the, alanine:glyoxylate aminotrans-
e 5′-phosphate; CHO, Chinese
xclusion chromatography; PBS,
pentaethylene glycol)ester; IFM,
microscopy; BSA, bovine serum
39 0458027170.
ights reserved.Pex5p peroxisomal import carrier [4,5]. In PH1, the deﬁcit of functional
AGT allows glyoxylate to escape peroxisomes and to be oxidized to ox-
alate by cytosolic L-lactate dehydrogenase. The overproduction of oxa-
late, an end-product of metabolism excreted in the urine, leads to the
progressive deposition of calcium oxalate crystals in the kidneys and
urinary tract causingurolithiasis and/or nephrocalcinosis. This ultimate-
ly causes renal failure and the consequent systemic oxalosis with calci-
um oxalate precipitation in the whole body [6]. Currently, the curative
treatments available for PH1 are the administration of pyridoxine, a pre-
cursor of the PLP coenzymewhich is effective in a minority (25–35%) of
the patients, and liver transplantation, a very invasive procedure [7].
The AGXT gene is present in European and North American popula-
tion as two main polymorphic variants, the major allele (frequency
~80%) and the minor allele (frequency ~20%) [8,9]. The latter differs
from the major allele by a 74 bp-duplication in intron 1 and by two
pointmutations leading to the P11L and I340Mamino acid substitutions
[9]. In the recombinant puriﬁed form, the protein encoded by theminor
allele (AGT-Mi) and that encoded by the major allele (AGT-Ma) share
similar spectroscopic and kinetic features although AGT-Mi has a less
stable dimeric structure in both the apo and the holo-form [10,11]. At
a cellular level, the presence of the minor allele allows a small portion
of AGT (~5%) to be rerouted from peroxisomes to mitochondria [9]
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tions found in PH1 [11].
The vastmajority of the PH1-causingmutations identiﬁedon theAGXT
gene are single base pair substitutions that lead to the synthesis of an ab-
errant gene product [12]. Until now, the molecular effect of only a few
mutations has been analyzed by a biochemical and/or a cell biology
approach. These studies have indicated that missense mutations can
cause functional (loss of catalytic activity, reduced coenzyme binding
afﬁnity), structural (reduced stability, reduced dimerization, aggregation
propensity in vitro and/or in the cell) and/or subcellular localization ef-
fects (aberrant mitochondrial localization) [10,13–24,11,25,26,9,27].
Gly161 is a highly conserved residue and represents a hot-spot
mutation site within the AGT sequence. In fact, three pathogenic muta-
tions that affect the GCC triplet in exon 4 of the AGXT gene have been
reported: the G161R mutation, co-segregating with the major allele,
and the G161S and G161C mutations, both co-segregating with the
minor allele [17,28]. The AGT crystal structure reveals that Gly161 is
far from the active site and is part of the loop 154–168 located in the
large domain in close contact with the small domain (Fig. 1) [4]. The
substitution of the small side chain of glycinewith the larger side chains
of arginine, serine or cysteine is predicted to perturb the folding of both
domains of the protein [20]. Studies on recombinant puriﬁed proteins
have recently shown that theG161S andG161Cmutations do not signif-
icantly alter the functional properties of AGT, but reduce the thermal
stability of the protein more in the apo- than in the holo-form, thus
pointing to the mutation mainly inducing a structural defect [20]. In
agreement with these results, crude Escherichia coli lysates expressing
the G161C-Mi, G161S-Mi and G161R-Ma variants display very low
AGT speciﬁc activity and expression level [28] and cell-free expression
experiments indicate that the G161R-Ma variant is prone to proteasomal
and tryptic degradation [17,18]. Although these data conﬁrm that themu-
tation ofGly161 could induce structural perturbations inAGT, the study of
the variants in a cellular environment and of the molecular mechanisms
underlying their pathogenicity is still lacking.
In the present work, by exploring the behavior of the Gly161 variants
in a cellularmodel systemand by analyzing the proteins in their recombi-
nant puriﬁed form, we show that (i) the molecular defect of the variants
only concerns their apo dimeric forms, which form cytosolic aggregates
and are susceptible to intracellular degradation and (ii) PLP binding
is able to reduce the aggregation extent of the variants by shifting the
equilibrium from the apo- to the non-aggregating holo-form. These re-
sults allow us to better deﬁne the molecular defect of Gly161 variants,
adding to our knowledge of mechanisms underlying AGT deﬁciency in
PH1 and providing directions for treatment in patients bearingmutations
at Gly161.Fig. 1. Position of the Gly161 residue in the AGT structure.Crystal structure of AGT (PDB code1H0C
small domain and theN-terminal extension are colored orange, green and yellow, respectively. O
sticks, and the loop 154–168 is colored blue. The inset shows the position and the microenviro2. Materials and methods
2.1. Materials
PLP, pyridoxine, L-alanine, sodium glyoxylate, rabbit muscle L-lactic
dehydrogenase, isopropyl-β-D-thiogalactoside (IPTG), EDTA and imid-
azole were purchased from Sigma. Ham's F12 Glutamax medium was
purchased from Invitrogen. All other chemicals were of the highest
purity available. The rabbit polyclonal anti-AGT human and guinea-pig
anti-peroxisomal protein antibodies were kindly provided by Prof. C.J.
Danpure, University College London, UK [11,29–33]; the anti-rabbit
HRP antibody was purchased from GE Healthcare. Oligonucleotides for
site directed mutagenesis were purchased from MWG Biotech AG
(Anzinger, Germany).
2.2. Site directed mutagenesis
The cDNA encoding human AGT has been cloned in the mammalian
expression vector pcDNA3.1/V5-His-TOPO, by means of the TOPO clon-
ing kit (Invitrogen). The desiredmutations were introduced on the vec-
tor by the QuikChange site-directed mutagenesis kit (Stratagene), by
using the previously reported oligonucleotides [20]. The E. coli expres-
sion vectors of the polymorphic and pathogenic variants of AGT were
constructed starting from the pAGT-His construct that contains the
complete open reading frame of AGT cloned in a pTrcHis2A expression
plasmid as previously reported [20]. All the mutations were conﬁrmed
by entire DNA sequence analysis.
2.3. Cell culture and lysis
CHO cells were cultured at 37 °C under O2/CO2 (19:1) in Ham's F12
Glutamax medium (Invitrogen) supplemented with fetal bovine serum
(10%, v/v), penicillin (100 units/ml) and streptomycin (100 μg/ml). The
standard pyridoxine concentration in this medium is 0.3 μM. Cells were
transfectedwith Turbofect™ TransfectionReagent (Fermentas) according
to themanufacturer's instructions. Four hours after transfection cellswere
washed in phosphate buffered saline (PBS) and themediumwas changed
with complete Ham's F12. Where indicated, from two days before trans-
fection to the end of the experiment, cells were grown in the presence
of added 100 μM pyridoxine. Transfection experiments were designed
to minimize the variability introduced by transfection efﬁciency, which
was controlled either by registering the GFP signal by ﬂuorescence
microscopy after co-transfection with pmaxGFP (Lonza) and/or by
quantifying the neomycin selection gene by RT-PCR (see below). Only) inwhich onemonomer is colored gray,while in the othermonomer the large domain, the
n the coloredmonomer PLP is represented as red sticks, Gly161 is represented asmagenta
nment of Gly161.
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experiment variability ≤15% were used.
Cells were harvested after 24 h and lysed in PBS, pH 7.2, plus prote-
ase inhibitor cocktail (CompleteMini, Roche), by ﬁve freeze/thaw cycles
followed by addition of DNAse (100 units/ml) at room temperature
for 45 min. The whole cell extract was separated by centrifugation
(29,200 g, 10 min, 4 °C) to obtain the soluble fraction. The pellets
were then resuspended in an equal volume of denaturing gel loading
buffer to obtain the insoluble fraction. The protein concentration in
the total cell lysate and in the soluble fraction was measured using the
Bradford protein assay.
2.4. Transcript expression analysis
CHO cells were grown in a 6-well plate and transfected as described
above. Cells were harvested, washed with PBS, and RNA was extracted
using RNeasy mini kit (Qiagen). The cDNA was synthetized from 1 μg
of mRNA using the Superscript VILO cDNA synthesis kit (Invitrogen,
Carlsbad, CA) according to the manufacturer's instructions. RT-PCR
was performed using 3 μl of a 1:10 cDNA dilution in a 25 μl reaction vol-
ume using SYBR Premix Ex Taq master mix (TaKaRa) on a Corbett
RotorGene 6000 thermocycler. The reaction conditions were initial de-
naturation at 95 °C for 15 min followed by 45 cycles of PCR which in-
cluded 15 s melting at 95 °C, 30 s annealing at 55 °C and 30 s
extension at 72 °C. The samples were examined for the expression of
human AGT using the forward primer 5′-AGCCCAGGATGTACCATCAC-
3′ and the reverse primer 5′-GCCACCCATGATCTCAATGTC-3′. To
normalize for transfection efﬁciency the expression of neomycin
phosphotransferase was quantiﬁed using the forward primer 5′-
AGACAATCGGCTGCTCTGAT-3′ and the reverse primer 5′-AGTGACAA
CGTCGAGCACAG-3′. The amount of mRNA was calculated in relation to
the glyceraldehyde 3′-phosphate dehydrogenase (GAPDH) mRNA in
the same sample. Quantitation of individual transcripts was performed
using the ‘Comparative Quantitation’ software supplied by Corbett Re-
search for the RotorGene. Themean efﬁciency of a group of cycling curves
is calculated at the point that the cycling curves take off and used to cal-
culate a fold change according to the formula: fold change = efﬁciency
Ct1–Ct2, where Ct1 and Ct2 are the take off values of the cycling curves
being compared. All reactions were performed at least in duplicate.
2.5. Western-blot analysis and chemical cross-linking
Tenmicrograms of cell lysatewere loaded per lane on aMini Protean
TGX™ pre-cast gel (Biorad) along with the Precision plus protein
Kaleidoscope™ (Bio-Rad) molecular mass markers. Following transfer
on a nitrocellulosemembrane by the iBlot device (Invitrogen) themem-
brane was blocked in 5% bovine serum albumin (BSA) for 1 h at 37 °C.
For AGT detection the membrane was incubated with polyclonal rabbit
anti AGT serum (dilution 1:2000), washed three times in TBST (50 mM
Tris–HCl pH 7.5, 150 mM NaCl, 0.1% Tween 20) and then incubated
with peroxidase-conjugated anti rabbit IgG (dilution 1:1000). Blotted
proteins were detected with ECL® (Millipore), using the ChemiDoc
XRS Imaging System (Bio-Rad, Hercules, CA). For densitometry analysis
of western-blots, the band volume (intensity × mm2) was quantiﬁed
using the software Quantity One 4.6.3. Results were expressed relative
to the densitometry of AGT-Ma.
Cross-linkingwas performedwith bis-N-succinimidyl-(pentaethylene
glycol)ester (BS(PEG)5) (Pierce). After cell lysis, 25 μg of the whole lysate
were cross-linked with BS(PEG)5 at 1.25 mM concentration and
quenched in 50 mM Tris–HCl after 30 min. Ten micrograms of each
sample were analysed by western blot as described above.
2.6. Pulse-chase experiments
Two million cells were seeded in a 10 cm dish and transfected with
the pcDNA3.1 vectors encodingAGT-Ma, AGT-Mi, G161R-Ma, G161S-Mior G161C-Mi. Twenty-four hours after transfection cells were incubated
for 1 h in Dulbecco's Modiﬁed Eagle Medium (DMEM)withoutmethio-
nine and cysteine (Gibco) and pulse labeled with 50 μCi of 35S methio-
nine/cysteine (EasyTag™ EXPRESS 35S Protein Labeling Mix, [35S],
Perkin Elmer). The standard content of pyridoxine of the DMEMmedi-
um is 19.6 μM. After 30 min an excess of unlabelled amino acids was
added and cells were split and incubated in Ham's F12 medium for
chase periods from 4 to 48 h. The soluble fraction of each cell lysate
(50 μg) was incubated overnight with 2 μg of guinea-pig anti-AGT anti-
body on a rotator at 4 °C. Thereafter, the immunoprecipitation reaction
was performed at room temperature by adding 30 μl of agarose-protein
A (GE, Healthcare) to themixture and by incubating the solution for 1 h
on a rotator at room temperature. The immunoprecipitated complex
was pelleted by centrifugation at 29,200 g at 4 °C for 5 min, washed
three times with IP wash/lysis buffer (Thermo Scientiﬁc), and resus-
pended in 20 μl of denaturing gel loading buffer. Proteinswere separated
by SDS–PAGE and radiolabelled AGT was detected by autoradiography.
Band intensities were quantiﬁed using the software ImageJ in accordance
with the ImageJ user guide. For each sample, the relative intensity with
respect to that at the start of the chase (pulse) was used to calculate the
half-life. Autoradiography ﬁlms with different exposition times were
acquired in order to have data suitable for quantiﬁcation analyses.
2.7. Size exclusion chromatography (SEC)
SEC analyses of lysates of CHO cells were performed according to the
method of Siekierska A. et al. [34] by transfecting 9 × 106 of CHO cells
with the vector encoding AGT-Ma or the G161R-Ma variant. Twenty-
four hours after transfection cells were harvested and lysed in 500 μl
of PBS as previously described. Total lysates were then loaded onto a
Superdex S200 H10/30 column (GE Healthcare), equilibrated in PBS
plus 1 mM EDTA, 1 mM EGTA and 1 mM DTT, using an AKTA FPLC
system (Amersham Biosciences). The absorbance signal at 280 nm of
the eluate, representing the total protein content, was registered.
Trichloroacetic acid 20% (v/v) was added to each eluted fraction and
the samples were incubated overnight at 4 °C. After centrifugation at
16,000 g for 30 min, the precipitated protein was washed twice in PBS
and resuspended in 20 μl of denaturing gel loading buffer. Ten microli-
ters of each sample were separated by SDS–PAGE and immunoblotted
against anti-AGT.
2.8. Immunoﬂuorescence microscopy (IFM)
CHO cells were grown and transfected in a 24-well plate on glass cov-
erslips. Twenty-four hours after transfection cells were ﬁxed in 4% (w/v)
paraformaldehyde, permeabilized with 0.3% Triton X-100 in phosphate
buffer saline (PBS), and blocked in 3% BSA. For the immunolabelling,
rabbit polyclonal anti-human AGT and anti-peroxisomal protein form
guinea-pigwere used as primary antibodies [29–33], andAlexa Fluor con-
jugated antibodies (AF488 and AF555, Life technologies) were used as
secondary antibodies. Mitochondria were stained with Mitotracker Red
(CMXRos version, Molecular Probes, Invitrogen) and nuclei with DAPI.
The coverslips were mounted over slides in AF1 medium (Dako). The
images were captured using a confocal laser-scanning ﬂuorescence mi-
croscope Leica SP5 (Leica Microsystem, Manheim, Germany) at 63×
magniﬁcation and processed using Adobe Photoshop and ImageJ soft-
wares (Rasband, W.S., ImageJ, U. S. National Institute of Health, Bethesda,
Maryland, USA (http://rsb.info.nih.gov/ij/, 1997–2008).
2.9. Immunoelectron microscopy (IEM)
CHO cells transiently expressing AGT-Ma or G161R-Ma were ﬁxed
for 2 h in a mixture of 4% paraformaldehyde and 0.4% glutaraldehyde
in 0.2 M PHEM buffer (60 mM Pipes, 25 mM Hepes, 10 mM EGTA,
2 mM MgCl2 pH 6) and washed with a PBS–glycine solution. After
washing, cells were detached from the dishes by a cell scraper, pelleted
Fig. 2. Analysis of AGT expression in CHO cells expressing AGT-Ma, AGT-Mi and Gly161
variants. Twenty-four hours after transfection CHO cells were harvested and lysed;
cell lysates (10 μg) from CHO cells expressing different AGT variants were subjected
to SDS/PAGE, immunoblotted with anti-AGT from rabbit (1:2000) and then detected with
a chemiluminescent substrate. (A) Immunoblot; (B) immunoblot bands quantiﬁcation
performed by the software Quantity One 4.6.3. The immunoblot lanes and histogram bars
are coded as follows: 1. soluble and 2. insoluble fractions of AGT-Ma; 3. soluble and 4. insol-
uble fractions of AGT-Mi; 5. soluble and 6. insoluble fractions of G161R-Ma; 7. soluble and 8.
insoluble fractions ofG161S-Mi; 9. soluble and10. insoluble fractions ofG161C-Mi; 11.whole
cell lysate of untransfected CHO cells. Bar graphs represent the mean ± SEM. Data come
from the mean of three different experiments.
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The blocks were infused with 2.3 M sucrose at 4 °C overnight and fro-
zen in liquid nitrogen. Ultrathin cryosections were cut using a Leica
EM FC7 cryoultratome and picked up using a 1:1mix of 2%methylcellu-
lose and 2.3 M sucrose. Sections were mounted on formvar carbon-
coated copper grids, and the localization of AGT in the cryosections
was analyzed using the rabbit polyclonal anti-human AGT followed by
protein A conjugated with 10 nm gold particles. After labeling, the
cryosections were embedded in methylcellulose–uranyl acetate mix-
ture. Cryosections were further investigated using a FEI Tecnai-12 elec-
tron microscope (FEI, Einhoven, The Netherlands) equipped with a
Veletta CCD camera for digital image acquisition.
2.10. Enzyme activity measurement
AGT enzymatic activity of cell lysates of CHO cells expressing
AGT-Ma, AGT-Mi, G161R-Ma, G161S-Mi andG161C-Miwas determined
by incubating 90 μg of the soluble fraction of the lysate with 0.5 M
L-alanine and 10 mM glyoxylate at 25 °C in 100 mM potassium phos-
phate buffer pH 7.4 in the presence or in the absence of 200 μM PLP.
In order to obtain a detectable signal of pyruvate in the linear phase of
the kinetics, the reaction time was set to 30 min for AGT-Ma and AGT-
Mi and to 150 min for Gly161 variants. The reactions were stopped by
adding TCA 10% (v/v) and the pyruvate production was measured
using a spectrophotometric assay coupled with lactate dehydrogenase
as previously described [35].
2.11. Protein expression and puriﬁcation
The Gly161 variants in the His-tagged formwere expressed in E. coli
and puriﬁed with the procedure already described [36]. PLP (100 μM)
was added to the eluted protein to obtain the holo-form and the solu-
tionwas concentrated and extensivelywashedwith 100 mMpotassium
phosphate buffer, pH 7.4, using Amicon Ultra 10 concentrators
(Amicon). As isolated, Gly161 variants contain 2 mol of PLP per dimer,
as revealed by releasing the cofactor in 0.1 M NaOH and using the
extinction coefﬁcient of 6600 M−1 cm−1 at 388 nm. The apo form of
each variant was prepared as previously described [36]. The protein
concentration in the AGT samples was determined by absorbance
spectroscopy using an extinction coefﬁcient of 9.54 × 104 M−1 cm−1
at 280 nm [13].
2.12. Spectroscopic measurements
Absorption measurements were made with a Jasco V-550 spectro-
photometer with 1 cm path length quartz cuvettes at a protein concen-
tration of 1–10 μM in 100 mMpotassium phosphate buffer, pH 7.4. The
increase in turbidity following the aggregation of Gly161 variants was
monitored by measuring the absorbance at 600 nm as a function of
time under physiological conditions (150 mM ionic strength, pH 7.4,
37 °C).
Intrinsic ﬂuorescence emission spectra were recorded on a Jasco
FP-750 spectroﬂuorimeter equipped with a thermostatically controlled
cell holder by using 1 cm path length quartz cuvettes. Protein emission
spectra were taken from 300 to 500 nm (excitation at 280 nm) with
both the excitation and the emission slits set to 5 nm. The protein
concentration was 1 μM. CD spectra were registered with a Jasco-710
spectropolarimeter at 25 °C, by using 1 cm path-length cuvettes at
10 μM enzyme concentration. Dynamic light scattering (DLS) mea-
surements were performed on a Zetasizer Nano S device (Malvern
Instruments) equipped with a Peltier temperature controller by using
disposable 12.5 × 45-mm cells with stopper. The aggregation kinetics of
AGT-Ma, AGT-Mi, G161S-Mi and G161C-Mi was studied by incubating
each enzymatic species in potassiumphosphate buffer, pH 7.4 at different
ionic strength at 37 °C. The buffer was ﬁltered immediately before use to
eliminate any impurities.2.13. Statistical analysis
Experiments have been performed at least in triplicate. Statistic
analysis was performed with Origin® 7.03 (Origin Lab) or GraphPad
Prism Version 5.0 (GraphPad software, San Diego, CA, USA).
3. Results
3.1. Gly161 variants show a reduced expression level and enzymatic activity
in mammalian cells
In order to investigate how the mutation of Gly161 could alter the
expression and the activity of AGT in a cell environment, the G161R-
Ma, G161S-Mi and G161C-Mi variants were expressed in CHO cells.
We did not succeed in the generation of stable clones expressing the
variants, as a consequence of the high mortality of the transfected
cells probably caused by the accumulation of insoluble protein aggre-
gates (see below). CHO cells transiently expressing AGT-Ma, AGT-Mi
and the Gly161 variants were analyzed for AGT enzymatic activity and
expression level in the soluble fraction of the cellular lysate after 24 h.
As previously reported [24], the transaminase activity of AGT-Mi was re-
duced by only 40% with respect to AGT-Ma (288 ± 20 nmol pyruvate/
min/mg protein for AGT-Ma and 176 ± 15 nmol pyruvate/min/mg pro-
tein for AGT-Mi). The activity of G161R-Ma, G161S-Mi and G161C-Mi
was 0.9 ± 0.1, 2.1 ± 0.3 and 1.5 ± 0.3 nmol pyruvate/min/mg protein,
respectively. Moreover, Gly161 variants had a reduced expression level,
as shown by the intensity of the speciﬁc band of immunoreactive AGT.
The expression of G161R-Ma was 4% compared with that of AGT-Ma,
and that of G161S-Mi and G161C-Mi was 12% and 5%, respectively, com-
paredwith that of AGT-Mi (Fig. 2). Considering that theG161S andG161C
mutationsdonot affect the kcat of the overall transamination reaction [20],
the very low speciﬁc activity of Gly161 variants expressed in CHO cells
can be attributed to a strongly reduced expression level and/or to an
increased propensity to proteolytic degradation.
RT-PCR experiments allowed us to rule out any possible inﬂuence of
the mutations at transcriptional level. In fact, no signiﬁcant differences
were observed in the levels of themRNA transcripts for cells expressing
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Fig. 1). Therefore, the reduced expression of Gly161 variants originates
at the protein level.
3.2. Gly161 variants form cytosolic aggregates and show a reduced half-life
in mammalian cells
We compared the soluble and insoluble fractions of lysates of CHO
cells expressing AGT-Ma, AGT-Mi and the Gly161 variants by means of
western-blot. While in the case of AGT-Ma and AGT-Mi about 75–80%
of the protein was present in the soluble fraction, in the case of
G161R-Ma, G161S-Mi and G161C-Mi variants 93%, 84% and 91% of the
protein, respectively, was present in the insoluble fraction (Fig. 2). Al-
though it should be noted that the total amount of protein (soluble
plus insoluble fraction) present in Gly161 variants was lower with re-
spect to that of AGT-Ma or AGT-Mi, these data suggest that the low ex-
pression level of the variants could be at least partly due to protein
aggregation. In agreement with these results, two strong bands at 80–
90 kDa, corresponding to the two structural isoforms of dimeric AGT
[24], could be seen after cross-linking of the total lysates of cells ex-
pressing AGT-Ma or AGT-Mi. On the other hand, the cross-linking of
the total lysates of cells expressing Gly161 variants leads to the appear-
ance of a faint band at a molecular weight higher than 200 kDa, and to
the almost complete loss of immunoreactive monomeric and dimeric
species of AGT, as a consequence of the formation of high-molecular
weight aggregates that were unable to enter the gel (Supplementary
Fig. 2) [35].We conﬁrmed that Gly161mutation induced the intracellu-
lar aggregation of AGT by SEC experiments performed on AGT-Ma and
the G161R-Ma variant. Lysates of CHO cells expressing AGT-Ma or the
G161R-Ma variant were subjected to SEC and the absorbance signal
at 280 nm (representing the total protein content) was registered
(Fig. 3A). Then, in order to measure the AGT content in the eluate,
each eluted fraction was analyzed by western-blot (Fig. 3B). As
expected, AGT-Ma eluted between 15 and 16 ml, an elution volume
identical to that of the active dimeric protein in the puriﬁed form,
whereas the G161R-Ma variant mainly eluted in a broad peak from 7
to 11 ml, consistent with the formation of a mixture of aggregates
with apparent molecular weight from≈350 to more than 1000 kDa.
IFM studies were performed to deﬁne if the mutation of Gly161
could affect the subcellular localization of AGT. As expected, a clearFig. 3. Gel ﬁltration analyses of CHO cells expressing AGT-Ma and the G161R-Ma variant.
Twenty-four hours after transfection CHO cells were harvested and lysed. The total lysate
was loaded on a Superdex S200 H10/30 SEC column (A) Elution proﬁle (absorbance at
280 nm) of the total lysate of CHO cells expressing AGT-Ma (-), total lysate of CHO cells
expressing G161R-Ma (…) and recombinant puriﬁed AGT-Ma (- -). (B) Western blot
analyses of SEC fractions of CHO cells expressing AGT-Ma and G161R-Ma.peroxisomal localization of AGT was observed in CHO cells transiently
expressing AGT-Ma or AGT-Mi (Supplementary Fig. 3). However, intra-
cellular spots staining for AGT that did not colocalize either with the
peroxisomal or with the mitochondrial marker were present in CHO
cells transiently expressing G161R-Ma, G161S-Mi or G161C-Mi (Fig. 4,
Supplementary Fig. 4). For the G161S-Mi and G161C-Mi variants, a
qualitative analysis of the confocal images indicated a partial peroxi-
somal localization of AGT. Notably, under these experimental condi-
tions, no signiﬁcant mitochondrial localization of AGT-Mi, G161S-Mi
and G161C-Mi could be seen (Supplementary Fig. 4). The comparison
of AGT-Ma and G161R-Ma by IEM revealed that AGT-Ma expressed in
CHO cells appeared to be clustered in electron-dense organelles
compatible with peroxisomes (Fig. 5A) [35]. In contrast, G161R-Ma
was detected mainly in structures with irregular shape varying from
200 to 300 nm to several microns in size compatible with cytosolic ag-
gregates (Fig. 5B).
Coulter-Mackie and Lian [17] reported cell-free transcription/
translation experiments indicating that the G→ Rmutation at position
161 strongly increases the susceptibility of AGT to proteasomal degra-
dation. Thus we determined the half-life of AGT-Ma, AGT-Mi and
Gly161 variants expressed in CHO cells. The data reported in Fig. 6
show that: (i) AGT-Ma and AGT-Mi are very stable, displaying half-
lives of 29 ±2 h and 27 ± 3 h, respectively, and (ii) the G161R-Ma,
G161S-Mi and G161C-Mi variants show a lower intracellular stability
with respect to AGT-Ma or AGT-Mi, displaying half-lives of b4 h,
13 ± 2 h, and 10 ±1 h, respectively.
Altogether, these data indicate that the reduced expression level of
Gly161 variants is due to their high propensity to form cytosolic aggre-
gates and to their greater susceptibility to intracellular degradationwith
respect to AGT-Ma and AGT-Mi.
3.3. Gly161 variants are present in the cell in the apo-form
Although it is clear that cytosolic aggregation and intracellular deg-
radation are the molecular defects shared by the three Gly161 variants,
the speciﬁc form (apo and/or holo in the dimeric and/or monomeric
form) responsible for the defects needs to be identiﬁed. To achieve
some insights into this issue, we investigated the intracellular levels of
apo- and holo-AGT by determining the AGT catalytic activity in the sol-
uble fraction of the cellular lysates both in the presence of added PLP in
the assay mixture, in order to measure the total amount of folded AGT
(holo plus apo), and in the absence of added PLP in the assay mixture,
in order tomeasure only the amount of holoAGT [24]. The difference be-
tween the two measurements represents the amount of apoAGT. As
shown in Fig. 7A, the speciﬁc activity of cells expressing Gly161 variants
was only detectable when PLP was present in the assay mixture, while
the activity of cells expressing AGT-Ma and AGT-Mi showed an about
40% increase after PLP addition. This indicates that the majority of
AGT-Ma and AGT-Mi is present in the holo-form, whereas Gly161
variants are almost entirely in the apo-form.
3.4. The addition of pyridoxine to the culture medium partly reduces the
aggregation extent of Gly161 variants
To gain insights into the possible effect of the addition of the coen-
zyme to the culture medium of Gly161 variants, starting from two
days before transfection to the end of the experiment cells were
grown in the presence of 100 μM pyridoxine, a vitamer of vitamin B6
known to be converted to PLP inside the cell [37]. It should be men-
tioned that the basal pyridoxine content of the medium is 0.3 μM. We
found that (1) the enzymatic activity of G161R-Ma, G161S-Mi and
G161C-Mi grown in the presence of 100 μM pyridoxine was 3.5, 2.5
and 2.1 fold higher, respectively, with respect to that of each variant
grown in the basal medium, and (2) when 100 μM pyridoxine was
present in the culture medium, the enzymatic activity of AGT-Ma,
AGT-Mi and Gly161 variants did not increase upon addition of PLP to
Fig. 4. Subcellular distribution of Gly161 variants in CHO cells. Twenty-four hours after transfection cells were ﬁxed and colored as follows: anti-AGT (green) and anti-peroxisomal proteins
(red). Nuclei were stained with Dapi (blue). Merge and single channel images come from a single z-plane. Individual color channel intensities have been selectively increased for better
visualization. Scale bar: 10 μm. White arrows pointing to peroxisomes and orange arrows pointing to large cytosolic aggregates are shown.
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holo-form inside the cell. It should be noted that the speciﬁc activity of
AGT-Ma and AGT-Mi dropped by about 25% in the presence of pyridox-
ine in the culturemedium, a result possibly due to a previously observed
inhibitory effect of the excess B6 vitamers [38] currently under investi-
gation. Western-blot analyses showed that the presence of added pyri-
doxine to the culture medium did not change the total amount of
expressed AGT of any of the analyzed enzymatic species (data not
shown). However, the amount of AGT present in the soluble fraction
of lysates of G161R-Ma, G161S-Mi and G161C-Mi cultured in the pres-
ence of 100 μM pyridoxine was 2.5, 3 and 2.8 fold higher, respectively,
as compared with that of each variant cultured in the basal medium
(Fig. 7B). These results suggest that the addition of the coenzyme shifts
the equilibrium from the apo to the holo-form and that this partly pre-
vents the aggregation of Gly161 variants.Fig. 5. IEM analyses of CHO cells expressing AGT-Ma or G161R-Ma. Twenty-four hours after transf
the anti-AGT antibody followed by protein A conjugated with 10 nm gold particles. Scale bar:3.5. Recombinant puriﬁed G161S-Mi and G161C-Mi variants in the apo-form
are unstable and prone to aggregation under physiological conditions
On the basis of the results reported in Sections 3.4 and 3.5, it is rea-
sonable to hypothesize that the aggregates could derive from the apo-
form of Gly161 variants. To test this hypothesis, the analysis of the
behavior of the variants in the recombinant puriﬁed form under physi-
ological conditions was undertaken. As previously reported [20], when
G161S-Mi and G161C-Mi were overexpressed in E. coli, a large portion
of the protein was present in the insoluble fraction and the puriﬁcation
yield was about 10% compared to that of AGT-Ma. Unfortunately, if the
G161R-Ma variant was expressed using the same procedure, the
expression level was less than 5% with respect to AGT-Ma and the mu-
tant protein was insoluble in crude extracts. Any attempt to increase
protein solubility by lowering the expression temperature, by addingection CHO cells expressing AGT-Ma (A) and the G161R-Ma variant (B) were stained with
150 nm.
Fig. 6. Measurement of the half-life of AGT-Ma, AGT-Mi, and Gly161 variants in CHO cells.
Transiently transfected CHO cells were pulse labeled with 35S Cys-Met mix containing
DMEM and then incubated in complete Ham's F12 medium for a chase time from 0
to 48 h. The standard content of pyridoxine of the DMEM medium is 19.6 μM, while
that of the Ham's F12 medium is 0.3 μM. The soluble fraction of the cell lysates was
immunoprecipitated with the anti-AGT antibody and loaded on SDS–PAGE; the signal of
radiolabelled AGT was detected by autoradiography. Band intensities were quantiﬁed
using the software ImageJ in accordance with the ImageJ user guide. For each sample,
the relative intensity with respect to that at the start of the chase (pulse) was used to
calculate the half-life.
Fig. 7. Effect of pyridoxine on the speciﬁc activity and expression level of AGT-Ma, AGT-Mi and
Gly161 variants.Where indicated, from two days before transfection to the end of the ex-
periment, cells were grown in the presence of added 100 μMpyridoxine. The basal level of
pyridoxine in the culture medium is 0.3 μM. Twenty-four hours after transfection cells
were harvested and lysed. (A) The soluble cell lysate (100 μg) was incubated with 0.5 M
L-alanine and 10 mM glyoxylate both in the absence (white) and in the presence (gray)
of 200 μM PLP. The amount of pyruvate produced was determined and expressed as
speciﬁc activity (nmol pyruvate/min/mg protein). (B) The soluble cell lysate (15 μg) was
subjected to SDS/PAGE, immunoblotted with anti-AGT from rabbit (1:2000) and detected
by chemiluminescence. The band shown for all enzymatic species in (B) is those of a single
gel. Data are representative of three different experiments. Bar graphs represent the
mean ± SEM.
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strains overexpressingmolecular chaperones like GroEL/GroES, was un-
successful. Therefore, we could not characterize the puriﬁed G161R-Ma
variant.
Turbidity changes of AGT-Mi, G161C-Mi and G161S-Mi incubated
under physiological conditions (37 °C, pH 7.4 and 150 mM ionic
strength) were monitored. While no changes in the absorbance at
600 nm could be detected for holo- and apo-AGT-Mi (data not shown)
and for the variants in the holo-form, a signiﬁcant change in turbidity in-
dicating an ongoing aggregation process was observed for apoG161S-Mi
and apoG161C-Mi (Fig. 8A and B). The aggregation extent is similar for
the two proteins, even if in the case of the G161C-Mi variant a decrease
in turbiditywasobserved after 40 mindue to aggregates precipitation.No-
tably, the addition of excess exogenous PLP (100 μM)decreased, even if at
different degrees, the extent of aggregation of both apoG161S-Mi and
apoG161C-Mi (Fig. 8). This result indicates that the binding of the coen-
zyme competeswith the aggregation process and is able to shift the equi-
librium versus the non-aggregating holoenzymatic form. In this regard it
should be noticed that the rate constants of association of 100 μM PLP to
apoAGT-Mi, apoG161S-Mi and apoG161C-Mi were equal to 0.28 ±
0.02 min−1, 0.18 ± 0.03 min−1 and 0.14 ± 0.01 min−1, respectively.
DLS studieswere undertaken to characterize the species present in so-
lution during the incubation of AGT-Mi, G161S-Mi and G161C-Mi underFig. 8. Time-dependent turbidity changes of puriﬁed G161S-Mi and G161C-Mi variants. Absor-
bance changes at 600 nm as a function of time of G161S-Mi (A) and G161C-Mi (B) at 2 μM
concentration in the apo-form (square), holo-form (triangle) and apo-forms + 100 μM
PLP (circle). The buffer was 60 mM potassium phosphate, pH 7.4, at 37 °C.
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the increase in the count rate, a parameter that depends on both the
size and the quantity of the particles, was very slow for the holoenzymes
and for apoAGT-Mi, a remarkable and fast aggregation process could be
seen for apoG161S-Mi and apoG161C-Mi, with the count rate leveling
off after ~20 and ~30 min, respectively (Fig. 9). The plots of the particle
size against time reported in Fig. 10 showed that, although small aggre-
gates (200–600 nm) were formed upon incubation of holo- and
apoAGT-Mi, holoG161S-Mi and holoG161C-Mi, the signal of the dimer
was continuously present. Thismeans that the dimerwas themost abun-
dant species in solution, since the contribution to scattering from larger
particles dominates the DLS signal, as the scattering intensity is propor-
tional to the sixth power of a particle diameter. On the contrary, the signal
of the dimer of apoG161S-Mi and apoG161C-Mi disappeared after 5–
10 min and aggregates of ~1500 nm were formed. Moreover, after
~40 min apoG161C-Mi formed a distinct population of high-order aggre-
gates (~5000 nm) that could explain the precipitation phenomenon seen
in turbidimetry experiments (Fig. 8A). It should also be pointed out that
the aggregation extent of the apovariants increased as the protein con-
centration increases, thus indicating that the aggregation did not depend
on protein monomerization. Moreover, when the associative behavior of
the variants was monitored at different ionic strengths (from 0.15 to
1.25 M), it could be observed that the aggregation extent increased as
the ionic strength decreased (Supplementary Fig. 5). This result indicates
that electrostatic forces mediate the interaction between dimers of
apoG161S-Mi and apoG161C-Mi, possibly due to the impact of Gly161
mutations on the tertiary structure of apoAGT. In this regard, we found
that in 0.1 M potassium phosphate buffer, pH 7.4, at 25 °C (i.e. under ex-
perimental conditions in which no aggregation occurs) the spectroscopic
features of holo G161S and G161C were similar to those of holoAGT-Mi
[22]. On the other hand, in comparison with apo AGT-Mi, apoG161C-Mi
and apoG161S-Mi were characterized by (i) a different near-UV dichroic
spectrum, as shown by a decreased ellipticity at 288 nm and an increased
ellipticity at 265 nm, and (ii) a 5 nm red-shift of the intrinsic ﬂuorescence
emission maximum, (data not shown).
Altogether, the results obtained allowed us to conclude that the
mutation of Gly161 to Ser or Cys on the background of the minor allele
(i) changes the tertiary structure of apoAGT and slows down PLP bind-
ing, and (ii) under physiological conditions, makes AGT in the apo-form
prone to a time-dependent aggregation, which is prevented by the
binding of PLP.Fig. 9. Time-dependent aggregation of AGT-Mi and Gly161 variants under physiological
conditions. The total count rate (measured as kilo counts per second) of AGT-Mi and
Gly161 variants is plotted as a function of time. Symbols: triangle: AGT-Mi, square:
G161S-Mi, circle: G161C-Mi. Open and closed symbols represent the holo- and apo-forms,
respectively. All measurements have been performed at 1 μM enzyme concentration,
37 °C, in 60 mM potassium phosphate buffer, pH 7.4.
Fig. 10. Time-dependent changes of the apparent diameter of AGT-Mi and Gly161 variants
under physiological conditions. The diameter of the species present in solution as function
of time is reported for the indicated species in the holo and apo-form. Symbols: black
open square: holo dimer, red open circle: apo dimer, black closed square: holo aggregates,
red closed circle: apo aggregates, red open triangle: high-molecular weight aggregates. All
measurements have been performed at 1 μM enzyme concentration, 37 °C, in 60 mM
potassium phosphate buffer, pH 7.4.4. Discussion
4.1. Gly161 mutations cause a folding defect of AGT
In this study we provide a detailed characterization of themolecular
and cellular effects of three missense mutations of AGT at position 161
leading to PH1: the G161R mutation, associated to the major allele,
and the G161S and G161C mutations, associated to the minor allele.
We show that: (i) the mutations of Gly161 strongly reduce the AGT ex-
pression level, both in E. coli and in amammalian cellularmodel, and the
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(ii) when expressed in CHO cells, Gly161 variants form insoluble aggre-
gates that localize in the cell cytosol; (iii) the substitution of Gly161
strongly reduces the AGT intracellular half-life in the order (G161R N
G161C N G161S), in agreement with previous cell-free expression
system studies [17]; (iv) under physiological conditions, puriﬁed
G161S-Mi and G161C-Mi variants in the apo-form are prone to an
electrostatically-driven aggregation. All in all, these results indicate
that Gly161 variants, although at different extents, are mainly character-
ized by a folding defect such that it is the inability of themutated peptide
chain to achieve or maintain a fully functional conformation, rather than
the loss of protein functionality per se, that causes the disease. Therefore,
the mutation is expected to induce a conformational change ultimately
responsible for the propensity of the protein to both degradation and
aggregation.
4.2. Proposedmolecular mechanism of the pathogenicity of Gly161 variants
We found that Gly161 variants expressed in CHO cells were entirely
present in the apo-formbecause no enzymatic activitywas detectable in
the absence of PLP in the assaymixture (Fig. 7A). This result can be part-
ly explained by the slower PLP binding rate of puriﬁed Gly161 variants
with respect to AGT-Mi and implies that the molecular defects of
these variants rely in their apo forms, prone to intracellular aggregation
and susceptible to degradation. Both these events are responsible for
the reduced expression level of the proteins. Notably, DLS measure-
ments revealed aggregation propensity of the recombinant apo-forms
of Gly161 variants, and not of their corresponding holo-forms, thus
reinforcing the view that cytosolic aggregates originate from the apo
form of the variants.
Previous DLS studies on puriﬁed G161S-Mi and G161C-Mi [20] and
SEC analyses of lysates of CHO cells expressing G161R-Ma (Fig. 3) did
not reveal the presence of monomeric AGT. Moreover, we show here
that the aggregation extent of the apovariants is proportional to protein
concentration and increaseswithdecreasing ionic strength. Thesedata in-
dicate that the variants in the dimeric form are prone to a self-association
process mediated by the electrostatic interaction between patches of op-
posite charge. AGT shows a highly positive charge distribution around its
surface [14]. Thus,whatever the conformational change caused byGly161
mutation is, it can be hypothesized that it could lead to the exposure of
negatively charged surfaces. This would create a dipole segregation of
charges that leads to the electrostatic aggregation of the protein, similarly
to what previously found for pathogenic variants of AGT bearing muta-
tions at Gly41 [14]. Following this view, it is reasonable to think that the
conformational change induced by Gly161 mutation could also cause
the exposure of stretches susceptible to proteolytic degradation. Although
this would explain the enhanced intracellular degradation of the variants,
a direct evidence for this interpretation is lacking.
On the basis of the results obtained, and taking into consideration
previous data on the response of AGT to chemical stress [10], a plausible
model that describes the molecular defect of Gly161 variants can be
outlined (Fig. 11A). Previous studies performed under chemical stress
conditions have suggested that in the AGT foldingpathway theunfolded
polypeptide chain (U) generatesmonomeric AGT (M) passing through a
partly folded monomeric intermediate (M*). M then dimerizes (D) and
binds PLP (DPLP) [39]. The conformational change affecting Gly161 var-
iants probably alters the positive electrostatic surface of apoAGT leading
to the exposure of negative patches. This makes the apodimeric form
(D) susceptible to a self-assembly process that competeswith PLP bind-
ing and leads to the formation of high-molecular weight aggregates
(AGGD). Thus, the molecular defect of Gly161 variants seems to affect
mostly the apo-form of the protein, as previously found for other path-
ogenic variants [10,15]. However, Gly161 variants show a peculiar be-
havior, because they form large aggregates that localize in the cell
cytosol, as indicated by IFM and IEM analyses. In fact, the increased pro-
pensity to aggregation in both non-cellular and cellular systems is not anovelty in the array of enzymatic phenotypes leading to AGT deﬁciency
[14,15,22,40], but only the formation of intraperoxisomal aggregates of
AGT has been already reported in liver biopsies of PH1 patients and in
CHO cells expressing the G41R-Mi variant [19,24]. Moreover, although
we do not know if the ultrastructure of the aggregates formed by
Gly161 variants is similar to that of the intraperoxisomal aggregates
formedbyGly41 variants, some considerations on the cytosolic localiza-
tion of Gly161 variants can be made. It is unlikely that the behavior of
Gly161 could depend on their inability to interact with the peroxisomal
carrier Pex5p, as themutation site is far from the interaction site [5] and
both G161S-Mi and G161C-Mi show a low peroxisomal localization.
Nevertheless, considering that the aggregation kinetics of puriﬁed
apoG161S-Mi and apoG161C-Mi under physiological conditions is
faster than that previously reported for the G41R-Mi variant [14], it
seems likely that the self-assembly of Gly161 variants occurs so rapidly
that large aggregates are formed before the import can take place. This
model can also explain the absence of a mitochondrial localization
of G161S-Mi and G161C-Mi. Fargue S. et al. [24] reported that some
destabilizing mutations cosegregating with the minor allele poly-
morphism lead to a mitochondrial mistargeting of the protein. The
mislocalization is the result of a synergism between the polymorphic
P11L mutation, which unmasks a putative mitochondrial targeting se-
quence [8,41], and the pathogenic mutations, which promote the accu-
mulation of unfolded or partly folded monomeric species compatible
with the mitochondrial import machinery. In the case of the G161S-Mi
and G161C-Mi variants, the pathogenic mutation does not allow the
accumulation of monomeric species, which would favor the mitochon-
drial import. However, it cannot be excluded that the mitochondrial
localization is prevented by the short-term expression of the protein,
which could foster a peroxisomal localization [24].
4.3. PLP is able to partly reduce the effects of Gly161mutation by decreasing
the aggregation extent of the variants
Treatment with vitamin B6 is a common strategy for the therapy of
manymetabolic diseases caused by PLP-dependent enzymes. However,
the degree of responsiveness is extremely variable depending on the
disease, the genotype and the enzymatic phenotype of the patients
[42–47]. Pyridoxine administration is effective in about 25–35% of PH1
patients and clinical data suggest that the responsive mutations are
those associated with AGT mistargeting [48–50]. Although it is known
that pyridoxine administration increases the intracellular concentration
of PLP, the molecular bases of the effect of the coenzyme are still under
investigation with both biochemical and cell biology approaches
[10,15,38,21]. The evidences reported in this study suggest that (i) in
the CHO cellular model, pyridoxine treatment increases the enzymatic
activity of Gly161 variants by preventing protein aggregation and
(ii) the addition of PLP reduces the aggregation extent of puriﬁed
G161S-Mi and G161C-Mi variants by converting the apo- to the more
stable holo-form. Thus, the coenzyme reduces the aggregation of the
variants both in a non-cellular and in a cellular environment by shifting
the equilibrium from the apodimer to the holodimer (Fig. 11A). There-
fore the coenzyme seems to play essentially a prosthetic role. This is
also conﬁrmed by the ﬁnding that the total amount of AGT was not in-
creased in the presence of added pyridoxine, thus suggesting that the
coenzyme does not prevent protein degradation, in agreement with
previous evidences indicating that the addition of PLP does not increase
the half-life of the G161R-Ma variant [17]. However, it should be consid-
ered that the medium used for pulse-chase experiments has a standard
pyridoxine content of 19.6 μM, which could promote holoenzyme for-
mation and prevent the detection of the effect of added coenzyme.
4.4. Conclusions
A particular feature of PH1 is the extreme variability of enzymatic
phenotypes by which missense mutations can lead to AGT deﬁciency.
Fig. 11. Schematic representation of the effect of pathogenic mutations on the folding pathway of AGT. (A) Proposed folding pathway of Gly161 variants. (B) Representation of the enzymatic
phenotypes leading to AGT deﬁciency. U: unfolded monomer, M*: partially folded monomer, M: folded monomer, D: apodimer, DPLP: PLP-bound dimer, DPMP: PMP (pyridoxamine
5′-phosphate)-bound dimer, AGGD: aggregates of apodimer, AGGDPLP: aggregates of holodimer. The pathogenic AGT variants are indicated as follows: A: Gly41 variants [14,19,24];
B: G82E-Ma [13,27]; C: F152I-Mi [15,24]; D: G170R-Ma [10,11,24]; E: Gly161 variants [18, this paper]; F: D183N [20]; G: S187F [25].
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while somemutations only cause a functional defect, the large majority
of them interferewith AGT folding causingdifferent downstreameffects
(Fig. 11B). In our work, we analyzed the effects of the Gly161 mutation
by combining studies on a mammalian cellular system, which give in-
sights into the effect of themutation on the expression level, subcellular
localization and intracellular stability of the protein, with analyses on
the puriﬁed variants, which give insights into the effect of the mutation
on the kinetic properties, the tertiary and the quaternary structure of
the protein. The combination of the results obtained allowed us to iden-
tify a new enzymatic phenotype leading to AGT deﬁciency, i.e. the for-
mation of cytosolic apoaggregates (Fig. 11B). Although PH1 patients
bearingmutations at Gly161 identiﬁed until now are compoundhetero-
zygous [28,51], it should be predicted that at least 25% of the AGT
expressed by these patients is formed by homodimers of Gly161 vari-
ants whose enzymatic phenotype could be partially interpreted on the
basis of our results in the cellular model system. Moreover, it cannot
be excluded that the pathogenic mechanism identiﬁed in this work
could apply to other pathogenic mutations leading to effects similar to
those caused by Gly161 substitution, thus affecting a larger number of
patients. Finally, on the basis of our results, pyridoxine administration
can be proposed as a ﬁrst line option for PH1 patients bearingmutations
at Gly161. However, considering the high susceptibility to intracellular
degradation of Gly161 variants and the limited effect of pyridoxine ontheir speciﬁc activities, vitamin B6 administration should be associated
with other molecules able to either speciﬁcally improve the folding
efﬁciency of the variants, such as pharmacological chaperones, or to en-
hance the general folding ability of the cell, such as proteostasis regula-
tors [52].
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